Harrow Health (HROW) Posts Earnings Results, Misses Estimates By $0.07 EPS

Harrow Health (NASDAQ:HROW) announced its quarterly earnings results on Tuesday. The company reported $0.77 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.84 by ($0.07), Fidelity Earnings reports. Harrow Health had a negative net margin of 16.81% and a negative return on equity of 231.16%. The company had revenue of $11.38 million during the quarter, compared to analysts’ expectations of $10.92 million.

Shares of Harrow Health stock traded down $0.65 during trading on Thursday, reaching $5.40. The company’s stock had a trading volume of 9,999 shares, compared to its average volume of 213,687. The company has a debt-to-equity ratio of 2.84, a current ratio of 1.13 and a quick ratio of 0.88. The stock has a market capitalization of $158.52 million, a price-to-earnings ratio of -9.17 and a beta of 0.07. Harrow Health has a 1-year low of $1.71 and a 1-year high of $7.20.

In other news, Director Robert J. Kammer sold 10,000 shares of the firm’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $6.91, for a total value of $69,100.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 13.78% of the stock is owned by company insiders.

Separately, Zacks Investment Research cut Harrow Health from a “hold” rating to a “sell” rating in a research report on Wednesday.

ILLEGAL ACTIVITY WARNING: “Harrow Health (HROW) Posts Earnings Results, Misses Estimates By $0.07 EPS” was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://www.chaffeybreeze.com/2019/03/14/harrow-health-hrow-posts-earnings-results-misses-estimates-by-0-07-eps.html.

Harrow Health Company Profile

Harrow Health, Inc owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients.

Featured Story: Return on Equity (ROE)

Earnings History for Harrow Health (NASDAQ:HROW)

Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.